For research use only. Not for therapeutic Use.
DCZ0415(Cat No.:I017385)is a small molecule inhibitor that targets the signaling pathway of the protein kinase B (AKT), a key regulator of cell survival, growth, and metabolism. By inhibiting AKT, DCZ0415 has shown promise in preclinical studies for its potential to suppress tumor growth, particularly in cancers that rely on aberrant AKT activation for survival and proliferation. Its mechanism of action also suggests potential use in other diseases characterized by dysregulated cell signaling, such as diabetes and cardiovascular conditions. Further research is needed to evaluate its safety, efficacy, and therapeutic applications in clinical settings.
Catalog Number | I017385 |
CAS Number | 2242470-43-3 |
Molecular Formula | C₂₃H₂₀N₂O₂ |
Purity | ≥95% |
Target | Apoptosis |
IUPAC Name | 4-[4-(pyridin-4-ylmethyl)phenyl]-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-ene-3,5-dione |
InChI | InChI=1S/C23H20N2O2/c26-22-20-16-5-6-17(19-12-18(16)19)21(20)23(27)25(22)15-3-1-13(2-4-15)11-14-7-9-24-10-8-14/h1-10,16-21H,11-12H2 |
InChIKey | LOXMLWHUIONWMI-UHFFFAOYSA-N |
SMILES | C1C2C1C3C=CC2C4C3C(=O)N(C4=O)C5=CC=C(C=C5)CC6=CC=NC=C6 |
Reference | [1]. Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018. |